What is PIMAVANSERIN used for?

PIMAVANSERIN (brand name pimavanserin) is a Other indicated for See full prescribing information.

What are the most common side effects of PIMAVANSERIN?

Reported side effects vary by individual. The side-effects section on this page lists the events most frequently reported to FDA FAERS for PIMAVANSERIN. FAERS is voluntary reporting, so it reflects what was reported, not absolute incidence.

Is PIMAVANSERIN the same as pimavanserin?

pimavanserin is a brand name for PIMAVANSERIN. They share the same active ingredient and FDA-approved indications. Biosimilars and authorised generics may differ in inactive ingredients such as buffers or preservatives.

PIMAVANSERIN

Q: How does PIMAVANSERIN work?

PIMAVANSERIN works through the following mechanism: 12.1 Mechanism of Action The mechanism of action of pimavanserin in the treatment of hallucinations and delusions associated with PDP is unclear. However, the effect of pimavanserin could be mediated through a combination of inverse agonist and antagonist activity at serotonin 5-HT 2A receptors and to a lesser extent at serotonin 5-HT 2C receptors..

Other

Brand names: pimavanserin

Oral

Mechanism of Action

12.1 Mechanism of Action The mechanism of action of pimavanserin in the treatment of hallucinations and delusions associated with PDP is unclear. However, the effect of pimavanserin could be mediated through a combination of inverse agonist and antagonist activity at serotonin 5-HT 2A receptors and to a lesser extent at serotonin 5-HT 2C receptors.

Indications

See full prescribing information

Contraindications

• 4 CONTRAINDICATIONS Pimavanserin is contraindicated in patients with a history of a hypersensitivity reaction to pimavanserin or any of its components. Rash
• urticaria
• and reactions consistent with angioedema (e.g.
• tongue swelling
• circumoral edema

FDA Warnings

5 WARNINGS AND PRECAUTIONS QT Interval Prolongation: Increases in QT interval; avoid use with drugs that also increase the QT interval and in patients with risk factors for prolonged QT interval
1 Increased Mortality in Elderly Patients with Dementia-Related Psychosis Antipsychotic drugs increase the all-cause risk of death in elderly patients with dementia-related psychosis
Analyses of 17 dementia-related psychosis placebo-controlled trials (modal duration of 10 weeks and largely in patients taking atypical antipsychotic drugs) revealed a risk of death in the drug-treated patients of between 1
Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4

Known Side Effects

5 documented side effects by frequency

Drug Not Working

>10%

Falls

1-10%

Condition Worsened

0.1-1%

UTI

0.1-1%

Drowsiness

0.1-1%

Community Discussions

No community discussions found for PIMAVANSERIN yet.

Primary sources

Every figure on this page links back to its primary source. See data sources for full provenance.

DailyMed FDA label search → PIMAVANSERIN openFDA label JSON → PIMAVANSERIN FAERS adverse-event reports → PIMAVANSERIN ClinicalTrials.gov → completed Phase 2+ trials of PIMAVANSERIN

Compare With

0 available comparisons

No comparisons yet.

Formulations

Dosage Forms

Tablet

Route

Oral